STRO
Sutro Biopharma·NASDAQ
--
--(--)
--
--(--)
5.11 / 10
Netural
Money flow analysis shows a good score of 7.73/10, with small-cap inflows positive and overall flow exhibiting a net inflow despite recent price weakness. Analyst coverage is limited to one institution, but it is uniformly bullish (100% Buy). This alignment of strong fund inflows and bullish analyst sentiment provides a supportive backdrop that could counterbalance technical and fundamental headwinds.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-20
InstitutionCitizens
Times predicted2
Historical Win Rate50.0%
Is money flowing into or out of STRO?
- STRO holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.11/10 (Netural).
